Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | VHL | P40337 | 1/20 | 0.32 |
| ▸ | ELOC | Q15369 | 1/20 | 0.32 |
| ▸ | ELOB | Q15370 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12316702 | 0.86 | LMNA (0.37) | MAOBLMNAMAPTMEN1KMT2A | |
| SCHEMBL5407585 | 0.83 | PDE4B (0.31) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL7448616 | 0.83 | MEN1 (0.33) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL12316691 | 0.81 | LMNA (0.49) | MAOBLMNAMAPTGRM5VHL | |
| SCHEMBL5410275 | 0.80 | MAOB (0.34) | MAOBLMNAMAPTMEN1KMT2A | |
| SCHEMBL12316789 | 0.78 | PDE4B (0.45) | MAOBLMNAMAPTGRM5MAOA | |
| SCHEMBL5400102 | 0.77 | DRD1 (0.37) | MAOBLMNAMAPTGRM5MAOA | |
| SCHEMBL14053377 | 0.75 | NOTUM (0.42) | MAOBLMNAMAPTMEN1KMT2A | |
| SCHEMBL12316748 | 0.75 | PDE4A (0.38) | MAOBMEN1KMT2AL3MBTL1 | |
| SCHEMBL30543406 | 0.75 | MEN1 (0.46) | MAOBLMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249578-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-7241757-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2007-07-10 | — | — | US | disclosed |
| US-20040186090-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| US-6750243-B1 | COMPETITIVE INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASES, ESPECIALLY THROMBIN; chemical synthesis; anticoagulants; treatment of thrombosis | AstraZeneća AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1140820-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1140820-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035869-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249578-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, TFPI | MAOB 435/4885LMNA 1125/4885MAPT 4846/4885 |
| US-20040186090-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | MAOB 427/4885LMNA 976/4885MAPT 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.